Darryl J. Sleep

1.8k total citations
46 papers, 1.4k citations indexed

About

Darryl J. Sleep is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Darryl J. Sleep has authored 46 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Endocrinology, Diabetes and Metabolism, 19 papers in Surgery and 16 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Darryl J. Sleep's work include Lipoproteins and Cardiovascular Health (17 papers), Prostate Cancer Treatment and Research (14 papers) and Bone health and treatments (12 papers). Darryl J. Sleep is often cited by papers focused on Lipoproteins and Cardiovascular Health (17 papers), Prostate Cancer Treatment and Research (14 papers) and Bone health and treatments (12 papers). Darryl J. Sleep collaborates with scholars based in United States, Canada and United Kingdom. Darryl J. Sleep's co-authors include Maureen T. Kelly, Joel B. Nelson, Michael A. Carducci, Claude C. Schulman, Parvez Mulani, James C. Stolzenbach, Carolyn M. Setze, Fred Saad, Graeme S. Steele and Susan M. Buttler and has published in prestigious journals such as Journal of Clinical Oncology, Diabetes Care and Cancer.

In The Last Decade

Darryl J. Sleep

45 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Darryl J. Sleep United States	20	632	466	404	380	285	46	1.4k
Peter Whelan United Kingdom	25	1.5k 2.3×	650 1.4×	468 1.2×	458 1.2×	279 1.0×	87	2.5k
Eberhard Varenhorst Sweden	31	1.9k 3.0×	414 0.9×	536 1.3×	777 2.0×	278 1.0×	102	2.7k
Vincent Fradet Canada	24	934 1.5×	388 0.8×	92 0.2×	282 0.7×	315 1.1×	86	1.8k
Anthony L. Patterson United States	23	1.2k 2.0×	333 0.7×	333 0.8×	213 0.6×	200 0.7×	44	1.6k
Anton J. Bueschen United States	19	1.1k 1.8×	293 0.6×	202 0.5×	302 0.8×	179 0.6×	49	1.8k
Lionel L. Bañez United States	26	1.4k 2.2×	350 0.8×	153 0.4×	525 1.4×	477 1.7×	75	2.1k
J. Atkins United States	12	1.4k 2.2×	285 0.6×	472 1.2×	625 1.6×	397 1.4×	19	2.3k
Thomas Morris United Kingdom	23	1.1k 1.7×	234 0.5×	295 0.7×	338 0.9×	235 0.8×	59	1.6k
Jin-Qiu Yuan China	19	643 1.0×	152 0.3×	176 0.4×	496 1.3×	245 0.9×	36	1.5k
Raymond Lance United States	22	853 1.3×	168 0.4×	225 0.6×	188 0.5×	162 0.6×	40	1.2k

Countries citing papers authored by Darryl J. Sleep

Since Specialization

Citations

This map shows the geographic impact of Darryl J. Sleep's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Darryl J. Sleep with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Darryl J. Sleep more than expected).

Fields of papers citing papers by Darryl J. Sleep

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Darryl J. Sleep. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Darryl J. Sleep. The network helps show where Darryl J. Sleep may publish in the future.

Co-authorship network of co-authors of Darryl J. Sleep

This figure shows the co-authorship network connecting the top 25 collaborators of Darryl J. Sleep. A scholar is included among the top collaborators of Darryl J. Sleep based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Darryl J. Sleep. Darryl J. Sleep is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Goldberg, Anne C., Vera Bittner, Carl J. Pepine, et al.. (2011). Efficacy of Fenofibric Acid Plus Statins on Multiple Lipid Parameters and Its Safety in Women With Mixed Dyslipidemia. The American Journal of Cardiology. 107(6). 898–905. 9 indexed citations

Jones, Peter H., Anne C. Goldberg, Howard R. Knapp, et al.. (2010). Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia. American Heart Journal. 160(4). 759–766. 15 indexed citations

Jones, Peter H., Kenneth Cusi, Michael H. Davidson, et al.. (2010). Efficacy and Safety of Fenofibric Acid Co-Administered with Low- or Moderate-Dose Statin in Patients with Mixed Dyslipidemia and Type 2 Diabetes Mellitus. American Journal of Cardiovascular Drugs. 10(2). 73–84. 22 indexed citations

Kipnes, Mark, Eli M. Roth, Carolyn M. Setze, et al.. (2009). Year Two Assessment of Fenofibric Acid and Moderate-Dose Statin Combination. Clinical Drug Investigation. 30(1). 51–61. 18 indexed citations

Jones, Peter H., Michael H. Davidson, Anne C. Goldberg, et al.. (2009). Efficacy and safety of fenofibric acid in combination with a statin in patients with mixed dyslipidemia: Pooled analysis of three phase 3, 12-week randomized, controlled studies. Journal of clinical lipidology. 3(2). 125–137. 17 indexed citations

Goldberg, Anne C., Harold Bays, Christie M. Ballantyne, et al.. (2008). Efficacy and Safety of ABT-335 (Fenofibric Acid) in Combination With Atorvastatin in Patients With Mixed Dyslipidemia. The American Journal of Cardiology. 103(4). 515–522. 58 indexed citations

Bays, Harold, Peter H. Jones, Syed M. Mohiuddin, et al.. (2008). Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia. Journal of clinical lipidology. 2(6). 426–435. 44 indexed citations

Zhu, Tong, Walid M. Awni, Balakrishna Hosmane, et al.. (2008). ABT‐335, the Choline Salt of Fenofibric Acid, Does Not Have a Clinically Significant Pharmacokinetic Interaction With Rosuvastatin in Humans. The Journal of Clinical Pharmacology. 49(1). 63–71. 26 indexed citations

Nelson, Joel B., Joseph L. Chin, Fred Saad, et al.. (2008). Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone‐refractory prostate cancer. Cancer. 113(9). 2478–2487. 190 indexed citations

10.

Jones, Peter H., Harold Bays, Michael H. Davidson, et al.. (2008). Evaluation of a New Formulation of Fenofibric Acid, ABT-335, Co-Administered with Statins. Clinical Drug Investigation. 28(10). 625–634. 34 indexed citations

11.

Wu, Eric Q., Parvez Mulani, Max H. Farrell, & Darryl J. Sleep. (2007). Mapping FACT-P and EORTC QLQ-C30 to Patient Health Status Measured by EQ-5D in Metastatic Hormone-Refractory Prostate Cancer Patients. Value in Health. 10(5). 408–414. 71 indexed citations

12.

Sullivan, Patrick W., Parvez Mulani, Mayer Fishman, & Darryl J. Sleep. (2007). Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer. Quality of Life Research. 16(4). 571–575. 62 indexed citations

13.

Carducci, Michael A., Fred Saad, Per‐Anders Abrahamsson, et al.. (2007). A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone‐refractory prostate cancer. Cancer. 110(9). 1959–1966. 236 indexed citations

14.

Xiong, Hao, Robert A. Carr, Charles Locke, et al.. (2007). Dual Effects of Rifampin on the Pharmacokinetics of Atrasentan. The Journal of Clinical Pharmacology. 47(4). 423–429. 26 indexed citations

15.

Sullivan, Patrick W., Joel B. Nelson, Parvez Mulani, & Darryl J. Sleep. (2006). Quality of life as a potential predictor for morbidity and mortality in patients with metastatic hormone-refractory prostate cancer. Quality of Life Research. 15(8). 1297–1306. 60 indexed citations

16.

Creel, Patricia, William P. Petros, Jon P. Gockerman, et al.. (2006). Phase I/II study of docetaxel and atrasentan in men with metastatic hormone-refractory prostate cancer (HRPC). Journal of Clinical Oncology. 24(18_suppl). 14504–14504. 7 indexed citations

17.

Sleep, Darryl J., James B. Nelson, Daniel P. Petrylak, Jeffrey D. Isaacson, & Michael A. Carducci. (2006). Clinical benefit of atrasentan for men with metastatic hormone-refractory prostate cancer metastatic to bone. Journal of Clinical Oncology. 24(18_suppl). 4630–4630. 3 indexed citations

18.

Mathews, William B., Hayden T. Ravert, Ursula Scheffel, et al.. (2006). Synthesis and in vivo evaluation of a PET radioligand for imaging the endothelin-A receptor. Nuclear Medicine and Biology. 33(1). 15–19. 6 indexed citations

19.

Vogelzang, Nicholas J., James B. Nelson, Claude C. Schulman, et al.. (2005). Meta-analysis of clinical trials of atrasentan 10 mg in metastatic hormone-refractory prostate cancer. Journal of Clinical Oncology. 23(16_suppl). 4563–4563. 38 indexed citations

20.

Heaton, Janet, Jason W. Dean, & Darryl J. Sleep. (2002). Sequential administration enhances the effect of apomorphine SL in men with erectile dysfunction. International Journal of Impotence Research. 14(1). 61–64. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact